Welcome to our dedicated page for Zentek Ltd. news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek Ltd. stock.
Zentek Ltd. (Nasdaq: ZTEK, TSX-V: ZEN) is an intellectual property development and commercialization company focusing on next-generation healthcare solutions for prevention, detection, and treatment. Zentek is at the forefront of commercializing ZENGuard, a groundbreaking coating with 99% antimicrobial effectiveness, including activity against COVID-19. This technology has applications in a variety of fields, including surgical masks and HVAC systems.
The company operates a state-of-the-art production facility in Guelph, Ontario, and is ISO 13485:2016 certified. Zentek has developed a synergistic relationship with McMaster University to leverage an exclusive global license for their aptamer-based rapid pathogen detection technology. This partnership has led to promising results, including the C19HBA aptamer, which has shown therapeutic potential against SARS-CoV-2, outperforming leading monoclonal antibodies in preclinical trials.
Through its wholly-owned subsidiary Triera Biosciences Ltd., Zentek continues to advance its aptamer technology. Notably, their C19HBA aptamer has demonstrated robust preclinical efficacy in both prophylactic and therapeutic settings against various SARS-CoV-2 variants, including Omicron XBB 1.5. The company is now moving towards Phase 1 clinical trials and exploring further applications for their platform in infectious diseases and oncology.
In addition to healthcare, Zentek has made significant strides in the HVAC industry. The company's ZenGUARD™ Enhanced Air Filters aim to improve air quality without increasing energy consumption or emissions. Zentek's commitment to innovation is further evidenced by a series of partnerships and distribution agreements, including collaborations with Medwell Solutions LLC and DCL Supply Ltd. These partnerships aim to expand the market reach of Zentek's antimicrobial technologies.
Recent Achievements:
- Significant progress in preclinical trials for C19HBA aptamer as a therapeutic for SARS-CoV-2.
- A promising safety and toxicity profile for the C19HBA aptamer in preclinical tests.
- Exclusive distribution agreements for ZenGUARD™ Enhanced Surgical Masks in the U.S. with Medwell Solutions LLC and DCL Supply Ltd.
- Launch preparations for ZenGUARD™ Enhanced Air Filters in the HVAC market.
- Second patent for their GO-Ag+ nanocomposite as an antimicrobial agent, expanding its potential applications to both human and veterinary medicine.
Zentek continues to focus on commercializing its proprietary technologies, aiming to provide significant health benefits while also addressing environmental concerns. By offering innovative, safer, and greener products, Zentek seeks to give its commercial partners a competitive edge in their respective markets.
Zentek Ltd. (NASDAQ:ZTEK) has entered a Distribution Agreement with Southmedic Inc. for the distribution of its patented ZenGUARD™ surgical masks in Canada. Southmedic, a leading medical device distributor, aims to introduce ZenGUARD™ masks to hospitals, clinics, and long-term care facilities. This partnership is expected to secure stable demand in the surgical mask market, leveraging Southmedic's established network. Zentek’s ZenGUARD™ technology boasts 99% antimicrobial activity and enhanced filtration efficiency, reinforcing its value proposition in healthcare.
Zentek Ltd. (Nasdaq:ZTEK) announced the appointment of Mitch Swergold as the new Director of Investor Relations. Swergold brings extensive experience in technology investment as a former Senior Analyst and Portfolio Manager. His role will involve enhancing communication with investors and presenting updated business information. Concurrently, Zentek granted him 50,000 stock options at an exercise price of $1.93. The company's innovative products, particularly the antimicrobial ZenGUARD coating, continue to drive its mission in the healthcare sector.
Zentek Ltd. (NASDAQ:ZTEK) announced successful results from Phase 2 HVAC filter testing conducted by the National Research Council of Canada. The ZenGUARD™ coating applied to standard HVAC filters significantly reduced airborne contaminants without affecting airflow rates or energy consumption. This breakthrough could enhance air quality across various sectors, from healthcare to real estate. Zentek plans to further optimize filter configurations and finalize regulatory submissions, moving closer to commercializing ZenGUARD™ products.
Zentek Ltd. (NASDAQ:ZTEK) has been granted Patent Number 3,152,759 by the Canadian Intellectual Property Office for its ZenGUARD™ technology, which includes graphene-silver composites with antimicrobial uses. This patent, valid until September 20, 2041, supports applications in personal protective equipment (PPE) and HVAC systems. CEO Greg Fenton noted the significance of moving from concept to commercialization, emphasizing the importance of intellectual property and the technology's potential to enhance safety and environmental protection.
Zentek Ltd. (NASDAQ:ZTEK) has filed amended and restated audited financial statements for the year ending March 31, 2022. This update reflects necessary amendments requested by the Ontario Securities Commission due to changes in auditors. The amended financials now include the predecessor auditor's report for the comparative period. Zentek operates in the development of graphene and nanomaterials for healthcare, with its ZenGUARD™ coating demonstrating 99% antimicrobial activity, including against COVID-19.
Zentek Ltd. (NASDAQ:ZTEK) has announced a 4-year, $1.6M research project with the University of Toronto and Ford's Powertrain Engineering Research Development Centre to develop next-generation graphene-based battery materials. Funded in part by $1.2M from the Mitacs Accelerate program, the project aims to enhance energy density and charging rates for automotive batteries. Notably, Zentek has developed a patent-pending graphene-wrapped silicon anode material that demonstrates significant improvements in capacity and cycle stability, potentially revolutionizing electric vehicle battery technology.
Zentek Ltd. (NASDAQ:ZTEK) has been selected to present its ZenGUARD™ technology at the 12th Annual Global Summit on Regulatory Science in October 2022. The summit focuses on nanotechnology advancements in medical products, and Zentek will showcase its patent-pending antimicrobial coating, proven to have 99% efficacy against various pathogens. Notable speakers from global regulatory bodies, including the FDA and Health Canada, will also participate. Additionally, the company has granted options for 150,000 common shares at $1.93 to certain officers and employees.
Zentek Ltd. (Nasdaq: ZTEK) announced the results from its annual and special meeting held on September 29, 2022. Shareholders approved all resolutions, including the election of the board of directors, with high approval rates: Francis Dube (95.689%), Greg Fenton (98.98%), and Eric Wallman (99.530%). Other approved items include appointing BDO Canada LLP as auditors (98.871%) and adopting a long-term incentive plan (91.766%). Dr. Francis Dube expressed satisfaction with the strong support from shareholders as the company focuses on advancing nanotechnologies.
Zentek Ltd. (NASDAQ:ZTEK) announced that its Canadian patent application for its ZenGUARD™ technology, utilized in personal protective equipment (PPE) and HVAC systems, has been allowed by the Canadian Intellectual Property Office. All 54 claims in the application were granted, marking a significant milestone in Zentek's strategy for global patent protection. CEO Greg Fenton emphasized the importance of this achievement in validating the company's IP development model. ZenGUARD™ has demonstrated 99% antimicrobial activity, including against COVID-19, enhancing its commercial potential.
Zentek Ltd. (NASDAQ: ZTEK) announced that CEO Greg Fenton will present at the Sidoti Small-Cap Virtual Investor Conference on September 22, 2022, at 12:15 PM ET. This annual conference connects small-cap companies with institutional investors. Fenton highlighted the company's strong IP pipeline and opportunities, particularly with ZenGUARD™, which shows 99% antimicrobial activity. Investors can register for the event at Sidoti's website.
FAQ
What is the current stock price of Zentek Ltd. (ZTEK)?
What is the market cap of Zentek Ltd. (ZTEK)?
What is Zentek Ltd. specialized in?
What is ZENGuard?
What recent advancements has Zentek made in healthcare?
Who are Zentek's key partners?
What is Triera Biosciences Ltd.?
What is the latest news about Zentek?
Where is Zentek located?
What industries does Zentek serve?
What technology platforms does Zentek use?
How can I contact Zentek for more information?
